Shandong Boan Biotechnology Co (FRA:UJ9) Earnings Power Value (EPV): €-0.92 (As of Dec25)


FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
44 GF Score
Price €0.52
GF Value €1.69
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co Earnings Power Value (EPV)?

Shandong Boan Biotechnology Co FRA:UJ9 +0.97% 44 Earnings Power Value (EPV) is €-0.92 as of Dec25. GuruFocus rates FRA:UJ9 with a GF Score™ of 44/100 and a GF Value™ of €1.69. The stock has 5 warning signs investors should review.

As of Dec25, Shandong Boan Biotechnology Co's earnings power value is €-0.92. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Shandong Boan Biotechnology Co  (FRA:UJ9) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Shandong Boan Biotechnology Co Earnings Power Value (EPV) Related Terms


Shandong Boan Biotechnology Co Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co Earnings Power Value (EPV) Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
Get a 7-Day Free Trial 0.00 0.00 0.00 -1.01 -0.78

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.01 0.00 -0.78

FRA:UJ9 vs VRTX, REGN, ALNY: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Boan Biotechnology Co Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's Earnings Power Value (EPV) falls into.


FRA:UJ9
44GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Shandong Boan Biotechnology Co's "Earning Power" Calculation:

Average of Last 5 Years Last Year
Revenue 72.35
DDA 9.53
Operating Margin % -39.45
SGA * 25% 9.15
Tax Rate % 0.00
Maintenance Capex 32.22
Cash and Cash Equivalents 137.06
Short-Term Debt 56.95
Long-Term Debt 38.03
Shares Outstanding (Diluted) 575.57

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -39.45%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = €72.35 Mil, Average Operating Margin = -39.45%, Average Adjusted SGA = 9.15,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 72.35 * -39.45% +9.15 = €-19.3902759 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = €-19.3902759 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -19.3902759 * ( 1 - 0.00% ) = €-19.3902759 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 9.53 * 0.5 * 0.00% = €0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -19.3902759 + 0 = €-19.3902759 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Shandong Boan Biotechnology Co's Average Maintenance CAPEX = €32.22 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Shandong Boan Biotechnology Co's current cash and cash equivalent = €137.06 Mil.
Shandong Boan Biotechnology Co's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 38.03 + 56.95 = €94.974 Mil.
Shandong Boan Biotechnology Co's current Shares Outstanding (Diluted Average) = 575.57 Mil.

Shandong Boan Biotechnology Co's Earnings Power Value (EPV) for Dec25 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -19.3902759 - 32.22)/ 9%+137.06-94.974 )/575.57
=-0.92

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -0.92310937949434-0.52 )/-0.92310937949434
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of €-0.92 mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Earnings Power Value (EPV) of €-0.92 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's Earnings Power Value (EPV) too high?
Shandong Boan Biotechnology Co's current Earnings Power Value (EPV) is €-0.92. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Earnings Power Value (EPV) compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Earnings Power Value (EPV) of €-0.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Earnings Power Value (EPV) is €-0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Earnings Power Value (EPV) of €-0.92. The stock's GF Value™ is €1.69, compared to a current price of €0.52 — trading 69.2% below its estimated fair value. The current Earnings Power Value (EPV) is €-0.92. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Earnings Power Value (EPV) is €-0.92 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.52 is trading 69.2% below its estimated GF Value™ of €1.69.

Key valuation signals for FRA:UJ9:

  • Earnings Power Value (EPV): €-0.92
  • GF Value™: €1.69 vs. price of €0.52 (69.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for FRA:UJ9

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price
€1.69
GF Value